• FREE Shipping & Insurance on Orders Over $500
    FREE Shipping & Insurance on Orders Over $500
back to top

GLOBAL MARKETS-Stocks nurse record monthly gains ahead of ECB

Logo - The Daily Drill - Digging Deep for precious metal news

* Gilead's remdesivir shows promise in clinical trial

* MSCI world stocks heads for best month on record

* Major currencies in holding pattern

* Oil markets still wild, Brent last up 11.8%

* ECB to hold press conference at 1330 GMT

By Marc Jones

LONDON, April 30 (Reuters) - World stocks headed for their best month on record on Thursday, as encouraging early results from a COVID-19 treatment trial and expectations of more European Central Bank (ECB) stimulus later in the day helped ease the pain of February and March.

Europe saw a cautious morning with oil firm Shell's first dividend cut in 80 years, a record drop in euro zone first quarter GDP and a surge in German unemployment all giving traders an excuse for some pre-ECB profit taking.

Not that it mattered. Easing coronavirus worries mean the STOXX 600 is up more than 25% over the last six weeks. April will be Europe's best month since 2009 while for MSCI's World Index, it is looking like the best since it started in the late 1980s.

"We have gone back to a turbo-charged version of the great financial crisis," said Simon Fennell, a portfolio manager in William Blair's global equity team, referring to how markets have surged on mass central bank and government stimulus.

"Today we will also see if the ECB is going to go to 1 trillion or beyond with its PEPP program," he added, a reference to the central bank's beefed-up emergency bond buying scheme.

A 1.4% rise in MSCI's broadest index of Asia-Pacific shares, excluding Japan, kept it tracking towards a weekly gain of more than 5%, its best in three weeks.

Optimism was also driven by Wall Street's strong finish on Wednesday after partial results from a trial of Gilead's antiviral drug remdesivir, suggested it could help speed recovery from COVID-19, the respiratory disease caused by the new coronavirus.

Japan's Nikkei jumped 2.15% to a seven-week high and Australia's ASX 200 rose 2.4%, with the mood further supported by South Korea reporting no new domestic coronavirus cases for the first time since its Feb. 29 peak.

More caution was evident in other asset classes, with the U.S. dollar steady against most of the other major currencies and German Bund yields - which move inversely to prices - dipping to a one-month low ahead of the expected ECB moves.

"It's a hope-based rally rather than an evidence-based rally," said Anthony Doyle, cross-asset specialist at fund manager Fidelity International in Sydney.

There were still worries about a second wave of infections, he said, adding that huge piles of cash waiting to go back into the markets suggest investor confidence remained nervy.


It's not only equity markets that have rebounded sharply this month. Gold is set for its best month in four years and copper, which is seen as a something of bellwether of global industry, was on track for its best performance since December 2017.

Markets have been excited by the prospect of a COVID-19 treatment because it may help economies emerge from lockdowns.

Partial results from the 1,063-patient U.S. government trial of Gilead's remdesivir were hailed as "highly significant" by the top U.S. infectious disease official, Anthony Fauci.

They showed hospitalized COVID-19 patients given the drug recovered in 11 days, compared with 15 days for patients given a placebo, and a slightly lower death rate.

But since treatment hopes don't seem to take into account regulatory and distribution difficulties, should a treatment be found, currency and bond markets were more circumspect.

"Any positive medical development is helpful," said Westpac FX analyst Sean Callow. "But no-one should be counting on a major breakthrough - the key for markets is control of the spread of the virus."

The yield on benchmark U.S. 10-year Treasuries dipped to 0.6075 % meanwhile, after the U.S. Federal Reserve left interest rates near zero and gave no indication of lifting them any time soon.

BlackRock’s Chief Investment Officer of Global Fixed Income, Rick Rieder, who oversees $2.2 trillion of assets, said it showed the Fed was committed to doing "whatever it takes."

Blackrock expects the U.S. central bank to purchase the equivalent of at least $1.5 trillion in Treasuries over the remainder of the year. Along with other crisis-fighting measures its balance sheet will balloon by $7 trillion, or $26 billion per day.

"The magnitude of the policy response to this economic crisis is simply stunning," Rieder added.

With all that to digest, the dollar held its ground against the resurgent Australian dollar for the first time in a week and barely budged against the euro which was at $1.0875 as the ECB's 1145 GMT statement and 1230 GMT news conference loomed.

Gold was a touch higher at $1,715 per ounce and things were still wild in oil markets. Brent crude and U.S. crude futures rose $2.1 and $2.4 - or 11.8% and 16.2% a barrel - respectively amid optimism that a storage squeeze is not as bad as first feared, and that demand for fuel may soon return.

(Additional Reporting by Tom Westbrook in Singapore and Swati Pandey in Sydney; Editing by Alex Richardson, Kirsten Donovan)

Don’t miss a golden opportunity.

Now that you’ve gained a deeper understanding about gold, it’s time to browse our selection of gold bars, coins, or exclusive Sprott Gold wafers.

About Sprott Money

Specializing in the sale of bullion, bullion storage and precious metals registered investments, there’s a reason Sprott Money is called “The Most Trusted Name in Precious Metals”.

Since 2008, our customers have trusted us to provide guidance, education, and superior customer service as we help build their holdings in precious metals—no matter the size of the portfolio. Chairman, Eric Sprott, and President, Larisa Sprott, are proud to head up one of the most well-known and reputable precious metal firms in North America. Learn more about Sprott Money.

Learn More

Looks like there are no comments yet.